Screener
Teladoc Health TDOC Accounts Receivable, Credit Loss Expense (Reversal)
Accounts Receivable, Credit Loss Expense (Reversal) at other companies
Other financials
Where this comes from
Reported directly by Teladoc Health in its filing.
Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.
The source filing: Teladoc Health’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:54 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001477449-26-000038
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Stock-based compensation | 23,912 | 47,507 |
| Depreciation of property and equipment | 4,929 | 7,902 |
| Amortization of right-of-use assets | 3,394 | 4,190 |
| Provision for allowances for doubtful accounts | 807 | 377 |
| Deferred income taxes | (1,673) | (34,072) |
| Other, net | 2,812 | 2,049 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (28,647) | (8,497) |
ITEM 1. Financial Statements
FAQ
- What is Teladoc Health's accounts receivable, credit loss expense (reversal)?
- Teladoc Health (TDOC) reported accounts receivable, credit loss expense (reversal) of $886K in Q2 2026.
- How has Teladoc Health's accounts receivable, credit loss expense (reversal) changed year-over-year?
- Teladoc Health's accounts receivable, credit loss expense (reversal) increased by 178.6% year-over-year, from $318K to $886K.
- What is the long-term trend for Teladoc Health's accounts receivable, credit loss expense (reversal)?
- Over 3 years (2021 to 2025), Teladoc Health's accounts receivable, credit loss expense (reversal) has grown at a -96.1% compound annual growth rate (CAGR), from $16.94M to $1K.
Ask your AI about Teladoc Health's accounts receivable, credit loss expense (reversal).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude